NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc. (NGM) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0001426332 · NGM · NASDAQ · as of Jun 8, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0001426332 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) has submitted 528 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2019. As a Healthcare sector company with CIK 0001426332, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is NGM Biopharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent NGM Biopharmaceuticals, Inc. 10-K was filed on 2024-04-04 for fiscal year ending 2024. Historical NGM 10-K annual reports are available from 2008 through 2024.
Investors researching NGM Biopharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
NGM SEC Filings · 8 questionsNGM Biopharmaceuticals, Inc. (NGM) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 528 filings and access original documents at no cost. NGM Biopharmaceuticals, Inc.'s CIK is 0001426332.